Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc has demonstrated robust financial growth, achieving a 25% increase in top-line revenue during Q4, supported by a 17% rise in volume and a 5% lift in average selling prices, along with record revenue from patient and digital solutions. The company has shown consistent performance with a 21% revenue growth in Q3, driven by a 13% increase in volume, setting a historic high in cash collections in October. Additionally, CareDx is projected to see continued growth, raising revenue estimates for 2026 and 2027 due to anticipated high returns on investment from a significantly expanded sales force, positioning the company for further sales volume increases moving forward.

Bears say

CareDx Inc is facing a challenging financial outlook, highlighted by a projected $7.5 million negative revenue impact tied to upcoming LCD decisions, which reflects a significant portion of its annualized revenue. Additionally, revenue performance has shown signs of weakness, with Q3'25 testing volumes falling short of expectations despite a year-over-year increase, indicating potential issues with sustaining growth. Moreover, the company is trading at low multiples relative to both its revenue estimates and historical market averages, suggesting investor concerns regarding its ability to successfully commercialize new diagnostic solutions critical to its growth strategy.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.